Could Marrone Bio Innovations Inc (MBII) See a Reversal After Having Formed Several Months Descending Triangle Chart Pattern

November 21, 2017 - By Peter Erickson

Investors sentiment decreased to 0.86 in 2017 Q2. Its down 0.14, from 1 in 2017Q1. It dived, as 3 investors sold Marrone Bio Innovations Inc shares while 4 reduced holdings. 1 funds opened positions while 5 raised stakes. 11.88 million shares or 32.33% more from 8.98 million shares in 2017Q1 were reported.
Savant Capital Lc reported 0% stake. Raymond James Advisors Incorporated owns 16,961 shares. Morgan Stanley reported 520 shares. Geode Cap Ltd Liability Com stated it has 89,410 shares. Primecap Mngmt Ca reported 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Kansas-based Creative Planning has invested 0% in Marrone Bio Innovations Inc (NASDAQ:MBII). Vanguard Grp Inc reported 314,908 shares. Ardsley Advisory Prtnrs reported 3.68M shares or 0.81% of all its holdings. Bridgeway Cap Mgmt has invested 0% in Marrone Bio Innovations Inc (NASDAQ:MBII). Northern has invested 0% of its portfolio in Marrone Bio Innovations Inc (NASDAQ:MBII). Hanson Mcclain owns 10,000 shares or 0% of their US portfolio. Waddell Reed Fin invested in 4.71M shares or 0.01% of the stock. Ogorek Anthony Joseph New York Adv reported 300 shares. Spark Invest Mgmt Lc holds 60,800 shares. State Street has invested 0% in Marrone Bio Innovations Inc (NASDAQ:MBII).

The stock of Marrone Bio Innovations Inc (MBII) formed a descending triangle with $1.12 target or 9.00 % above today’s $1.03 share price. The 6 months triangle pattern indicates low risk for the $32.29 million company. If the $1.12 price target is reached, the company will be worth $2.91M more.
The descending triangle is in our view more reliable than the ascending one. The descending triangle pattern has break even failure rate for up and down breakouts of 7% and 16%, respectively. The average rise and decline is 47% and 16%. The throwback or so called pullback rates are: 37% and 54%. The stocks meeting their targets is high for this type of breakout: 84% and 54% percent.

About 33,932 shares traded. Marrone Bio Innovations Inc (NASDAQ:MBII) has risen 94.03% since November 21, 2016 and is uptrending. It has outperformed by 77.33% the S&P500.

Marrone Bio Innovations Inc (NASDAQ:MBII) Ratings Coverage

Among 3 analysts covering Marrone Bio Innovations (NASDAQ:MBII), 2 have Buy rating, 0 Sell and 1 Hold. Therefore 67% are positive. Marrone Bio Innovations had 6 analyst reports since August 11, 2015 according to SRatingsIntel. Piper Jaffray maintained Marrone Bio Innovations Inc (NASDAQ:MBII) on Friday, July 21 with “Hold” rating. The firm has “Buy” rating given on Wednesday, March 16 by Rodman & Renshaw. The firm has “Buy” rating given on Tuesday, August 11 by Zacks. The stock of Marrone Bio Innovations Inc (NASDAQ:MBII) earned “Buy” rating by H.C. Wainwright on Tuesday, August 15. On Friday, September 15 the stock rating was maintained by Piper Jaffray with “Hold”. The firm earned “Hold” rating on Monday, August 14 by Piper Jaffray.

More notable recent Marrone Bio Innovations Inc (NASDAQ:MBII) news were published by: Bizjournals.com which released: “New Marrone Bio product gets EPA approval” on November 01, 2017, also Globenewswire.com with their article: “ÉLÉPHANT VERT and Marrone Bio Innovations Sign Distribution Agreement in North …” published on September 19, 2017, Seekingalpha.com published: “Marrone Bio Innovations’ (MBII) CEO Pamela Marrone on Q3 2017 Results …” on November 14, 2017. More interesting news about Marrone Bio Innovations Inc (NASDAQ:MBII) were released by: Globenewswire.com and their article: “Marrone Bio Innovations Debuts Highlight Video from the Great Lakes …” published on September 14, 2017 as well as Finance.Yahoo.com‘s news article titled: “Marrone Bio (MBII) Q3 Earnings, Revenues Miss Estimates” with publication date: November 15, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.